Additional file 4: of Comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chemoprevention of hepatocellular carcinoma: a nationwide high-risk cohort study

Table S2. Antihypertensive medications (other than ACEIs and ARBs) for patients with HBV and HCV within 6 months after antihypertensive treatment, as grouped according to ACEI or ARB use within 6 months after the index date. (DOCX 20 kb)